Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 3, 2008, Pages

  Wang, Shuang ^a   Jiang, Jifu ^a,b   Guan, Qiunong ^b,c   Wang, Hao ^a,b   Nguan, Christopher Y C ^c   Jevnikar, Anthony M ^a,b   Du, Caigan ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Experimental therapy; Kidney transplantation; Transforming growth factor 1

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CREATININE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITROGEN; TRANSFORMING GROWTH FACTOR BETA1; UREA; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUOROBENZAMIDE; BENZAMIDE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MAP2K1 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG POTENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GRAFT RECIPIENT; GRAFT SURVIVAL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO CULTURE; KIDNEY CELL CULTURE; KIDNEY TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GRAFT REJECTION; KIDNEY; KIDNEY DISEASE; PATHOLOGY;

ANIMALS; BENZAMIDES; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; MALE; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSFORMING GROWTH FACTOR BETA1;

EID: 54449102401     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90285.2008     Document Type: Article

References (60)

1. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30: 105-116, 2003.
2. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS. Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752-757, 1993.
3. Bottinger EP, Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol 13: 2600-2610, 2002.
4. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65: 663-675, 1991.
5. Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F. Role of transforming growth factor-β1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 16 Suppl 1: 114-116, 2001.
6. Coupes BM, Newstead CG, Short CD, Brenchley PE. Transforming growth factor-β1 in renal allograft recipients. Transplantation 57: 1727-1731, 1994.
7. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
8. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556, 1993.
9. DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM, Scherle PA. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol 160: 4175-4181, 1998.
10. Du C, Jiang J, Guan Q, Yin Z, Masterson M, Parbtani A, Zhong R, Jevnikar AM. Renal tubular epithelial cell self-injury through Fas/Fas ligand interaction promotes renal allograft injury. Am J Transplant 4: 1583-1594, 2004.
11. Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol 160: 2579-2589, 1998.
12. Franceschini N, Cheng O, Zhang X, Ruiz P, Mannon RB. Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. Am J Transplant 3: 396-402, 2003.
13. Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, Uchida C, Aoki M, Hosono M, Kitagawa M, Hishida A. Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int 65: 63-74, 2004.
14. Hamar P, Liptak P, Heemann U, Ivanyi B. Ultrastructural analysis of the Fischer-to-Lewis rat model of chronic allograft nephropathy. Transpl Int 18: 863-870, 2005.
15. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-β-dependent responses in human mesangial cells. FASEB J 17: 1576-1578, 2003.
16. Hernandez-Fuentes MP, Lechler RI. Chronic graft loss. Immunological and non-immunological factors. Contrib Nephrol 146: 54-64, 2005.
17. Hornberg JJ, Tijssen MR, Lankelma J. Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4β-phorbol 12-myristate 13-acetate. Eur J Biochem 271: 3905-3913, 2004.
18. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
19. Hotchkiss H, Chu TT, Hancock WW, Schroppel B, Kretzler M, Schmid H, Liu Y, Dikman S, Akalin E. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 81: 342-349, 2006.
20. Jevnikar AM, Brennan DC, Singer GG, Heng JE, Maslinski W, Wuthrich RP, Glimcher LH, Kelley VE. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF-α. Kidney Int 40: 203-211, 1991.
21. Joosten SA, van Kooten C, Sijpkens YW, de Fijter JW, Paul LC. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int 65: 1556-1559, 2004.
22. + T cells. J Immunol 170: 2427-2434, 2003.
23. 1 integrin-mediated activation of the ERK/AP-1 pathway involved in collagen matrix remodeling by rat mesangial cells. J Cell Physiol 198: 470-478, 2004.
24. + T-lymphocytes induces pattern of chronic allograft nephropathy in a nude rat model. Transplantation 79: 753-761, 2005.
25. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50: 235-242, 1996.
26. Liu S, Liang Y, Huang H, Wang L, Li Y, Li J, Li X, Wang H. ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor-β1 stimulated glomerular podocytes. Cell Physiol Biochem 16: 207-216, 2005.
27. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23: 5281-5293, 2005.
28. Mannon RB. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 6: 867-875, 2006.
29. Mannon RB, Doyle C, Griffiths R, Bustos M, Platt JL, Coffman TM. Altered intragraft immune responses and improved renal function in MHC class II-deficient mouse kidney allografts. Transplantation 69: 2137-2143, 2000.
30. Mannon RB, Griffiths R, Ruiz P, Platt JL, Coffman TM. Absence of donor MHC antigen expression ameliorates chronic kidney allograft rejection. Kidney Int 62: 290-300, 2002.
31. Mannon RB, Kopp JB, Ruiz P, Griffiths R, Bustos M, Platt JL, Klotman PE, Coffman TM. Chronic rejection of mouse kidney allografts. Kidney Int 55: 1935-1944, 1999.
32. Mohamed MA, Robertson H, Booth TA, Balupuri S, Kirby JA, Talbot D. TGF-β expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation 69: 1002-1005, 2000.
33. + T cells and interferon-γ to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection. Transpl Immunol 14: 21-25, 2005.
34. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M, Awazu M. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 17: 1604-1614, 2006.
35. Ozdemir BH, Ozdemir FN, Demirhan B, Haberal M. TGF-β1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 80: 1681-1685, 2005.
36. Poggio ED, Clemente M, Riley J, Roddy M, Greenspan NS, Dejelo C, Najafian N, Sayegh MH, Hricik DE, Heeger PS. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 15: 1952-1960, 2004.
37. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late kidney allograft failure. Kidney Int 62: 1848-1854, 2002.
38. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs. cadaveric renal transplant recipients. JAMA 270: 1339-1343, 1993.
39. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64: 755-763, 2002.
40. Pribylova-Hribova P, Kotsch K, Lodererova A, Viklicky O, Vitko S, Volk HD, Lacha J. TGF-β1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int 69: 1872-1879, 2006.
41. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Marcussen N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y. The Banff 97 Working Classification of Renal Allograft Pathology. Kidney Int 55: 713-723, 1999.
42. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456-4462, 2004.
43. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial-to- mesenchymal cell transition. J Am Soc Nephrol 15: 390-397, 2004.
44. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-β signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 284: F243-F252, 2003.
45. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 9: 2135-2141, 1998.
46. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816, 1999.
47. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
48. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
49. Sharma VK, Bologa RM, Xu GP, Li B, Mouradian J, Wang J, Serur D, Rao V, Suthanthiran M. Intragraft TGF-β1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 49: 1297-1303, 1996.
50. Suzuki H, Uchida K, Nitta K, Nihei H. Role of mitogen-activated protein kinase in the regulation of transforming growth factor-β-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin Exp Nephrol 8: 188-195, 2004.
51. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 58: 369-385, 2007.
52. Tian YC, Chen YC, Chang CT, Hung CC, Wu MS, Phillips A, Yang CW. Epidermal growth factor and transforming growth factor-β1 enhance HK-2 cell migration through a synergistic increase of matrix metalloproteinase and sustained activation of ERK signaling pathway. Exp Cell Res 313: 2367-2377, 2007.
53. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor-β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263: 7741-7746, 1988.
54. Waaga AM, Gasser M, Kist-van Holthe JE, Najafian N, Muller A, Vella JP, Womer KL, Chandraker A, Khoury SJ, Sayegh MH. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 107: 909-916, 2001.
55. Wada T, Azuma H, Furuichi K, Sakai N, Kitagawa K, Iwata Y, Matsushima K, Takahara S, Yokoyama H, Kaneko S. Reduction in chronic allograft nephropathy by inhibition of p38 mitogen-activated protein kinase. Am J Nephrol 26: 319-325, 2006.
56. Wang S, Guan Q, Diao H, Lian D, Zhong R, Jevnikar AM, Du C. Prolongation of cardiac allograft survival by inhibition of ERK1/2 signaling in a mouse model. Transplantation 83: 323-332, 2007.
57. + T cells to generate a Th2-inducing cytokine environment. J Exp Med 202: 793-804, 2005.
58. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 16: 148-157, 2006.
59. Zhang M, Fraser D, Phillips A. ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-β1 autoinduction in proximal tubular epithelial cells. Am J Pathol 169: 1282-1293, 2006.
60. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.